Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff; Draft Document; Reopening of Comment Period

Summary

The Food and Drug Administration (FDA) is reopening the comment period for a draft document on postmarket safety surveillance for FDA staff, allowing interested persons more time to submit comments.